Ceria was founded to develop products from a proprietary platform technology to treat life-threatening human diseases characterized by overactive and dysregulated immune responses.
Ceria's platform technology consists of a novel active pharmaceutical agent comprised of a regulatory microRNA (miR-146a) conjugated to cerium nanoparticles (CNPs). Like all nanoparticles, CNPs are actively endocytosed by all cells they contact, delivering the miR-146a payload to targeted cells.
Multiple high morbidity and life-threatening conditions are characterized by dysregulated immune responses including acute respiratory distress syndrome (ARDS), diabetic foot ulcers (DFU) and ulcerative colitis (UC), representing a US market of $4B. Affected tissues in these conditions all demonstrate reduce miR-146a and are corrected by our candidate drug products.
Development to date has been supported by ~$7.5m of nondilutive financing and $500k investment capital. The company is seeking up to $3m in investment capital to contribute to a first-in-man clinical study of one drug product consisting of formulated CNP-miR-146a in DFU.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 1230 N Cherry Ln,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.ceriatx.com
- Keywords
- Therapeutics, Biotech, Critical care, Wound care, Respiratory therapeutics, Pulmonary inflammation, Inflammatory bowel disease, Crohn's Disease, Ulcerative colitis, Nanoparticles.
- HQ
- Tucson, Arizona
Ceria Therapeutics Questions
Ceria Therapeutics's website is http://www.ceriatx.com
Ceria Therapeutics's LinkedIn profile is https://www.linkedin.com/company/ceriatx
Ceria Therapeutics has
10 employees.
View email and phone details for 10
employees at Ceria Therapeutics.
Ceria Therapeutics's industry is
Biotechnology Research
Ceria Therapeutics's top competitors are
Gelsana,
Darwin Biosciences,
Mosaic Biosciences,
Vona Oncology,
Aoa Dx,
Think Bioscience,
Nuvox Therapeutics,
Inanobio,
Biodesix, Inc.,
Arpeggio Biosciences.
Ceria Therapeutics's categories are Biotechnology Research
Ceria Therapeutics's founding year is 2019
